Prostate Cancer Clinical Trials in Chicago

Showing 161-180 of 202 trials

Prostate Cancer Utilities and Cost-Effectiveness Analysis

NCT00203918

The purpose of this study is to help doctors and patients make better decisions about prostate cancer treatment. This research is being done because we do not know how patient preferences for health states related to prostate cancer affect the final treatment decision.

Prostate Cancer

University of Chicago481 participantsStarted Jan 2004

Chicago, Illinois, United States

COMPLETEDPHASE22.2 miles

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005810

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.

Prostate Cancer

Alliance for Clinical Trials in Oncology40 participantsStarted Mar 2000

San Francisco, California, United States • Chicago, Illinois, United States • Baltimore, Maryland, United States +4 more locations

Prostate Cancer Utilities and Cost-Effectiveness Analysis

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Prostate Cancer Trials in Other Cities

Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer

A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Sildenafil in Treating Erectile Dysfunction in Patients With Prostate Cancer

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer

Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Other Conditions in Chicago